Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219)

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 1, 1996, Pages 47-49

  Wise, R ^a   Mortiboy, D ^a   Child, J ^a   Andrews, J M ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TROVAFLOXACIN;

ADULT; ARTICLE; BLISTER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030064142     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.1.47     Document Type: Article

References (14)

1. Briggs-Gooding, B., and R. N. Jones. 1994. In vitro antimicrobial activity of CP-99,219 a novel aza-bicyclo-naphthyridone. Antimicrob. Agents Chemother. 37:349-353.
2. Brightly, K. E., T. D. Gootz, A. Girard, J. A. Sutcliffe, M. J. Castaldi, M. R. Anderson, R. Borovoy, J. Faiella, D. Girard, T. McKibben, and S. A. Miller. 1993. 7-(3-Azabicyclo[3.1.0]hexylquinolone antibacterial agents: synthesis and biological evaluation resulting in identification of CP-99,219, abstr 1509, p. 395 In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington. D C.
3. Catchpole, C., J. M. Andrews, J. Woodcock, and R. Wise. 1994. The comparative pharmacokinetics and tissue penetration of single dose ciprofioxacin 400 mg i.v. and 750 mg p o. J. Antimicrob. Chemother 33:103-110
4. Daniels, R. Personal communication.
5. Child, J., F. Boswell, N. Brenwald, J. M. Andrews, and R. Wise. 1995. The in vitro activity of CP-99,219, a new naphthyridone antimicrobial, a comparison with fluoroqumolone agents. J Antimicrob. Chemother 35:809-876.
6. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering. 1994 In vitro activity of CP-99,219 a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
7. Girard, D., T. D. Gootz, and K. E. Brighty. 1993. CP99.219. a novel 7-(3-azabicyclo [3.1.0] hexyl naphthyridine: pharmacokinetics in animals, abstr. 1511. p. 395. In Program and abstracts of the 33rd Tnterscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C.
8. Gomeni, R. 1984. GPHARM - an interactive graphic program for individual and population pharmacokinetic parameter estimations. Comput. Biol. Med. 14:25-34
9. Johnson, J. H., M. A. Cooper, J. M. Andrews, and R. Wise. 1992 Pharmacokinetics and inflammatory fluid penetration of sparfloxacin Antimicrob Agents Chemother. 36:2444-2446.
10. Karabalut, N., and G. L. Drusano. 1993. Pharmacokinetics of the quinolone antimicrobial agents, p. 195-224 In D. C. Hooper and J. S. Wolfson (ed.), Quinolone antimicrobial agents, 2nd ed. American Society for Microbiology, Washington, D.C.
11. Teng, R., S. C. Harris, D. Dix, J. Shentag, G. Foulds, B. M. Silber, R. P. Gladue, and T. E. Listan. 1993. Pharmacokinetics of CP99,219, a new quinolone antibiotic, following single oral doses to healthy volunteers, abstr. 1512, p. 395. in Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington. D.C.
12. Teng, R., T. E. Listan, L. C. Dogulo, and S. C. Harris. 1995. Multiple dose pharmacokinetics and safety of CP99,219 a new quinolone antibiotic in healthy volunteers, abstr. 4062. In Abstracts of the 19th International Congress of Chemotherapy Canadian Journal of Infectious Diseases, Ontario.
13. Wise, R., J. M. Andrews, and L. J. Edwards. 1983 In vitro activity of Bay 08967. a new quinolone derivative, compared with those of other antimicrobial agents. Antimicrob. Agents Chemother. 23:559-564.
14. Wise, R., A. P. Gillett, B. Cadge, S. R. Durham, and S. Baker. 1980. The influence of protein binding upon tissue fluid levels of six β-lactam antibiotics. J. Infect. Dis. 142:77-82.